LSV Asset Management raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 510,089 shares of the biotechnology company’s stock after purchasing an additional 29,600 shares during the period. LSV Asset Management’s holdings in United Therapeutics were worth $65,230,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Sun Life Financial INC purchased a new position in United Therapeutics during the second quarter valued at approximately $198,000. Unison Advisors LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $224,000. Balasa Dinverno & Foltz LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $260,000. Fox Run Management L.L.C. purchased a new position in United Therapeutics during the second quarter valued at approximately $269,000. Finally, IFM Investors Pty Ltd purchased a new position in United Therapeutics during the third quarter valued at approximately $301,000. 95.14% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the stock. Wedbush boosted their target price on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a report on Thursday, August 2nd. HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, August 2nd. Credit Suisse Group lowered their target price on shares of United Therapeutics from $106.00 to $103.00 and set an “underperform” rating on the stock in a report on Thursday, November 1st. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. Finally, BidaskClub downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 24th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $136.25.

UTHR stock opened at $121.49 on Friday. United Therapeutics Co. has a one year low of $100.57 and a one year high of $152.55. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $4.84 billion, a PE ratio of 7.91, a P/E/G ratio of 25.90 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 EPS for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. The company had revenue of $412.70 million during the quarter, compared to analysts’ expectations of $378.22 million. During the same period last year, the firm posted $4.69 EPS. United Therapeutics’s quarterly revenue was down 7.4% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Co. will post 14.28 EPS for the current year.

In related news, Director Christopher Causey sold 810 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the sale, the director now owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.20% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “LSV Asset Management Has $65.23 Million Holdings in United Therapeutics Co. (UTHR)” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/11/17/lsv-asset-management-has-65-23-million-holdings-in-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More: Understanding each part of a balance sheet

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.